Breast Cancer Coverage from Every Angle

Harold J. Burstein, MD, PhD, and William J. Gradishar, MD, on ER+ Breast Cancer: Coming Changes in Treatment

Posted: Thursday, March 16, 2017

Harold J. Burstein, MD, PhD, of Harvard Medical School and Dana-Farber Cancer Institute, talks with William J. Gradishar, MD, of the Robert H Lurie Comprehensive Cancer Center, about how SABCS 2016 presentations on CDK 4/6 inhibitors, mTOR inhibitors, and novel tools, such as genomic assays, will likely affect future iterations of the NCCN Guidelines for Breast Cancer. 

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.